Purple Biotech’s IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium
Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech’s CAPTN-3 platform of capped tri-specific antibodies, designed…
